Clusterin as a Potential Biomarker of Obesity-Related Alzheimer's Disease Risk
- PMID: 33110346
- PMCID: PMC7555556
- DOI: 10.1177/1177271920964108
Clusterin as a Potential Biomarker of Obesity-Related Alzheimer's Disease Risk
Abstract
Over 35% of the adult US population is obese. In turn, excess adiposity increases the risk of multiple complications including type 2 diabetes (T2D), insulin resistance, and cardiovascular disease; yet, obesity also independently heightens risk of Alzheimer's Disease (AD), even after adjusting for other important confounding risk factors including blood pressure, sociodemographics, cholesterol levels, smoking status, and Apolipoprotein E (ApoE) genotype. Among patients over the age of 65 with dementia, 37% have coexisting diabetes, and an estimated 7.3% of cases of AD are directly attributable to midlife obesity. Clusterin, also known as apolipoprotein J (ApoJ), is a multifunctional glycoprotein that acts as a molecular chaperone, assisting folding of secreted proteins. Clusterin has been implicated in several physiological and pathological states, including AD, metabolic disease, and cardiovascular disease. Despite long-standing interest in elucidating clusterin's relationship with amyloid beta (Aβ) aggregation/clearance and toxicity, significant knowledge gaps still exist. Altered clusterin expression and protein levels have been linked with cognitive and memory function, disrupted central nervous system lipid flux, as well as pathogenic brain structure; and its role in cardiometabolic disease suggests that it may be a link between insulin resistance, dyslipidemia, and AD. Here, we briefly highlight clusterin's relevance to AD by presenting existing evidence linking clusterin to AD and cardiometabolic disease, and discussing its potential utility as a biomarker for AD in the presence of obesity-related metabolic disease.
Keywords: Alzheimer’s Disease; adipose tissue; amyloid beta; clusterin.
© The Author(s) 2020.
Conflict of interest statement
Declaration of conflicting interests:The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
Similar articles
-
Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies.Front Neurosci. 2019 Feb 28;13:164. doi: 10.3389/fnins.2019.00164. eCollection 2019. Front Neurosci. 2019. PMID: 30872998 Free PMC article. Review.
-
ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy.Neuromolecular Med. 2016 Mar;18(1):99-108. doi: 10.1007/s12017-015-8381-7. Epub 2015 Dec 14. Neuromolecular Med. 2016. PMID: 26661731
-
Methionine oxidation of clusterin in Alzheimer's disease and its effect on clusterin's binding to beta-amyloid.Neurosci Lett. 2024 Jul 27;836:137874. doi: 10.1016/j.neulet.2024.137874. Epub 2024 Jun 9. Neurosci Lett. 2024. PMID: 38857696
-
Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice.Alzheimers Res Ther. 2019 May 10;11(1):42. doi: 10.1186/s13195-019-0498-8. Alzheimers Res Ther. 2019. PMID: 31077261 Free PMC article.
-
In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology.J Mol Neurosci. 2004;23(3):247-54. doi: 10.1385/JMN:23:3:247. J Mol Neurosci. 2004. PMID: 15181253 Review.
Cited by
-
Obesity impacts the expression of Alzheimer's disease-related genes: The Framingham Heart Study.Alzheimers Dement. 2023 Aug;19(8):3496-3505. doi: 10.1002/alz.12954. Epub 2023 Feb 22. Alzheimers Dement. 2023. PMID: 36811231 Free PMC article.
-
Clusterin Plasma Concentrations Are Decreased in Sepsis and Inversely Correlated with Established Markers of Inflammation.Diagnostics (Basel). 2022 Dec 1;12(12):3010. doi: 10.3390/diagnostics12123010. Diagnostics (Basel). 2022. PMID: 36553017 Free PMC article.
-
Apolipoprotein J Attenuates Vascular Restenosis by Promoting Autophagy and Inhibiting the Proliferation and Migration of Vascular Smooth Muscle Cells.J Cardiovasc Transl Res. 2022 Oct;15(5):1086-1099. doi: 10.1007/s12265-022-10227-y. Epub 2022 Mar 4. J Cardiovasc Transl Res. 2022. PMID: 35244876
-
Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity.Clin Exp Immunol. 2023 Apr 7;212(1):52-60. doi: 10.1093/cei/uxad011. Clin Exp Immunol. 2023. PMID: 36722378 Free PMC article.
-
The clusterin connectome: Emerging players in chondrocyte biology and putative exploratory biomarkers of osteoarthritis.Front Immunol. 2023 Mar 15;14:1103097. doi: 10.3389/fimmu.2023.1103097. eCollection 2023. Front Immunol. 2023. PMID: 37033956 Free PMC article.
References
-
- Alzheimer’s Association. Alzheimer’s disease facts and figures [Ebook]. https://www.alz.org/documents_custom/2018-facts-and-figures.pdf. Accessed June 20, 2020.
-
- Barnard ND, Bush AI, Ceccarelli A, et al. Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol Aging. 2014;35 Suppl 2:S74-S78. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous